Press "Enter" to skip to content

American Multinational Johnson & Johnson Stock Crashes

Johnson & Johnson shares inched 0.38% higher to $170.55 Monday. This proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.99% to 4,197.05 and the Dow Jones Industrial Average DJIA rising 0.54% to 34,393.98. This was the stock’s second consecutive day of losses.

Johnson & Johnson closed $3.10 below its 52-week high ($173.65), which the company reached on January 26th.The stock outperformed some of its competitors Monday, as Roche Holding AG Part. Cert. RHHVF fell 2.67% to $335.80, Merck & Co. Inc. MRK fell 0.19% to $79.03, and Pfizer Inc. PFE fell 0.35% to $39.81. Trading volume (5.2 M) remained 2.0 million below its 50-day average volume of 7.2 M

From 2016 to 2020, Johnson & Johnson’s sales increased from $71.9 to $82.6 billion, its adjusted earnings per share grew from $6.73 to $8.03, and its free cash flow rose from $15.5 billion to 20.2 billion. For a century-old company, those numbers are quite impressive. In 2021, the company is seeing continuous growth in growth momentum.

According to its latest earnings report, the company generated $22.3 billion in total sales in the first quarter of 2021, reflecting a 7.9% increase year-over-year. Its adjusted earnings came in at $2.59 per share for the quarter, up 12.6% from the $2.30 per share it earned in the year-ago period. J&J already had a deal with the U.S. government to supply 200 million doses of its COVID-19 vaccine.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *